MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification

Basit Öğe Kaydı
dc.WoS.categoriesOncologyen_US
dc.authorid0000-0003-0917-2098en_US
dc.contributor.authorÜnal, Çağlar
dc.contributor.authorÖzmen, Tolga
dc.contributor.authorDıuymaz, Tomris
dc.date.accessioned2024-04-16T10:50:23Z
dc.date.available2024-04-16T10:50:23Z
dc.date.issued2023-10-14
dc.description.abstractBackground: The minichromosome maintenance protein-2 (MCM-2) is a more sensitive proliferation marker than Ki-67. This study aimed to evaluate the relationship between MCM-2 and Oncotype DX recurrence score (ODX-RS) and determine an MCM-2 cutoff value in high-risk patients according to TAILORx risk categorization. Methods: Hormone receptor (HR) positive HER-2 negative early-stage breast cancer patients (pT1-2, pN0-N1, M0) who had ODX-RS were included in the study. According to the TAILORx trial, patients were divided into two groups with high (ODX-RS >= 26) and low risk (ODX-RS <26) in terms of ODX-RS. Formalin-fixed-paraffin-embedded tissues of patients were re-evaluated, and 3 mu m sections were prepared for MCM-2 immuno-histochemical staining. The relationship between ODX-RS and the percentage of MCM-2 staining was evaluated in two groups. The ROC curve analysis was performed to determine the MCM-2 cut-off value for the TAILORx high-risk group (ODX-RS >= 26). Results: The mean MCM-2 value was significantly higher in the high-risk group [(60.2 +/- 11.2 vs 34.4 +/- 13.8, p < 0.001)]. In the multivariate analysis, MCM-2 (OR: 1.27, 95% CI: 1.08-1.49, p = 0.003) and progesterone receptor (PR) levels <= 10% (OR: 60.9, 95% CI: 4.1-89.7, p = 0.003) were found to be independent factors indicating a high-risk group. A one-unit increase in MCM-2 level increased the likelihood of being in the high-risk group by 1.27 times. In the ROC curve analysis, the optimal MCM-2 cut-off level was 50 (AUC: 0.921, sensitivity: 86.7%, specificity: 96.0%, p < 0.001). Conclusion: Our study is the first study in the literature to investigate the relationship between ODX-RS and MCM-2 levels in HR-positive HER-2 negative early breast-cancer patients. In this study, MCM-2 was an independent risk factor in identifying high-risk patients according to TAILORx risk classification. MCM 2 cut-off value (50) may help the decision on adjuvant chemotherapy in patients where the Oncotype DX test cannot be performed.en_US
dc.fullTextLevelFull Texten_US
dc.identifier.doi10.2147/BCTT.S421535
dc.identifier.issn1179-1314
dc.identifier.pmid37674872en_US
dc.identifier.scopus2-s2.0-85170231032en_US
dc.identifier.urihttps://hdl.handle.net/11411/5261
dc.identifier.urihttps://doi.org/10.2147/BCTT.S421535
dc.identifier.wosWOS:001066053600001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.nationalInternationalen_US
dc.numberofauthors10+en_US
dc.pages659-669en_US
dc.publisherDOVE MEDICAL PRESS LTDen_US
dc.relation.ispartofBREAST CANCER-TARGETS AND THERAPYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectbreast canceren_US
dc.subjectMCM-2en_US
dc.subjectOncotype DX recurrence scoreen_US
dc.subjectTAILORx risk categorizationen_US
dc.titleMCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification
dc.typeArticle
dc.volume15en_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
2023WosDuymaz.pdf
Boyut:
2.77 MB
Biçim:
Adobe Portable Document Format
Açıklama:
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Faculty of Health Sciences
PubMed Indexed Publications
Scopus Indexed Publications
Web of Science Indexed Publications